GSK Flovent HFA approved
Executive Summary
GlaxoSmithKline's CFC-free version of Flovent (fluticasone) for the treatment of asthma as prophylactic therapy in adults and adolescents 12 years and older clears FDA May 14. The drug is the second HFA nasal steroid to be approved after Aventis' Nasacort HFA inhaler for allergic rhinitis was cleared in April (1"The Pink Sheet" April 12, 2004, In Brief). A proposed rule on CFC-containing products is near publication (2"The Pink Sheet" April 26, 2004, In Brief)...